IBDEI0HX ; ; 20-FEB-2013
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 20, 2013
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,24189,0)
 ;;=V10.87^^193^1651^12
 ;;^UTILITY(U,$J,358.3,24189,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,24189,1,1,0)
 ;;=1^V10.87
 ;;^UTILITY(U,$J,358.3,24189,1,8,0)
 ;;=8^Hx Of Thyroid Malignancy
 ;;^UTILITY(U,$J,358.3,24189,2)
 ;;=^295245
 ;;^UTILITY(U,$J,358.3,24190,0)
 ;;=V10.51^^193^1651^1
 ;;^UTILITY(U,$J,358.3,24190,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,24190,1,1,0)
 ;;=1^V10.51
 ;;^UTILITY(U,$J,358.3,24190,1,8,0)
 ;;=8^Hx Of Bladder Malignancy
 ;;^UTILITY(U,$J,358.3,24190,2)
 ;;=^295228
 ;;^UTILITY(U,$J,358.3,24191,0)
 ;;=V10.52^^193^1651^9
 ;;^UTILITY(U,$J,358.3,24191,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,24191,1,1,0)
 ;;=1^V10.52
 ;;^UTILITY(U,$J,358.3,24191,1,8,0)
 ;;=8^Hx Of Kidney Malignancy
 ;;^UTILITY(U,$J,358.3,24191,2)
 ;;=^295229
 ;;^UTILITY(U,$J,358.3,24192,0)
 ;;=V10.46^^193^1651^29
 ;;^UTILITY(U,$J,358.3,24192,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,24192,1,1,0)
 ;;=1^V10.46
 ;;^UTILITY(U,$J,358.3,24192,1,8,0)
 ;;=8^Hx-Prostatic Malignancy
 ;;^UTILITY(U,$J,358.3,24192,2)
 ;;=^295224
 ;;^UTILITY(U,$J,358.3,24193,0)
 ;;=V10.47^^193^1651^32
 ;;^UTILITY(U,$J,358.3,24193,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,24193,1,1,0)
 ;;=1^V10.47
 ;;^UTILITY(U,$J,358.3,24193,1,8,0)
 ;;=8^Hx-Testicular Malignancy
 ;;^UTILITY(U,$J,358.3,24193,2)
 ;;=^295225
 ;;^UTILITY(U,$J,358.3,24194,0)
 ;;=V10.49^^193^1651^23
 ;;^UTILITY(U,$J,358.3,24194,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,24194,1,1,0)
 ;;=1^V10.49
 ;;^UTILITY(U,$J,358.3,24194,1,8,0)
 ;;=8^Hx-Male Genit Malig Nec
 ;;^UTILITY(U,$J,358.3,24194,2)
 ;;=^295226
 ;;^UTILITY(U,$J,358.3,24195,0)
 ;;=V10.45^^193^1651^24
 ;;^UTILITY(U,$J,358.3,24195,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,24195,1,1,0)
 ;;=1^V10.45
 ;;^UTILITY(U,$J,358.3,24195,1,8,0)
 ;;=8^Hx-Male Genit Malig Nos
 ;;^UTILITY(U,$J,358.3,24195,2)
 ;;=^295223
 ;;^UTILITY(U,$J,358.3,24196,0)
 ;;=V10.3^^193^1651^4
 ;;^UTILITY(U,$J,358.3,24196,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,24196,1,1,0)
 ;;=1^V10.3
 ;;^UTILITY(U,$J,358.3,24196,1,8,0)
 ;;=8^Hx Of Breast Malignancy
 ;;^UTILITY(U,$J,358.3,24196,2)
 ;;=^295217
 ;;^UTILITY(U,$J,358.3,24197,0)
 ;;=V10.41^^193^1651^15
 ;;^UTILITY(U,$J,358.3,24197,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,24197,1,1,0)
 ;;=1^V10.41
 ;;^UTILITY(U,$J,358.3,24197,1,8,0)
 ;;=8^Hx-Cervical Malignancy
 ;;^UTILITY(U,$J,358.3,24197,2)
 ;;=^295219
 ;;^UTILITY(U,$J,358.3,24198,0)
 ;;=V10.42^^193^1651^34
 ;;^UTILITY(U,$J,358.3,24198,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,24198,1,1,0)
 ;;=1^V10.42
 ;;^UTILITY(U,$J,358.3,24198,1,8,0)
 ;;=8^Hx-Uterus Malignancy Nec
 ;;^UTILITY(U,$J,358.3,24198,2)
 ;;=^295220
 ;;^UTILITY(U,$J,358.3,24199,0)
 ;;=V10.43^^193^1651^11
 ;;^UTILITY(U,$J,358.3,24199,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,24199,1,1,0)
 ;;=1^V10.43
 ;;^UTILITY(U,$J,358.3,24199,1,8,0)
 ;;=8^Hx Of Ovarian Malignancy
 ;;^UTILITY(U,$J,358.3,24199,2)
 ;;=^295221
 ;;^UTILITY(U,$J,358.3,24200,0)
 ;;=V10.44^^193^1651^18
 ;;^UTILITY(U,$J,358.3,24200,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,24200,1,1,0)
 ;;=1^V10.44
 ;;^UTILITY(U,$J,358.3,24200,1,8,0)
 ;;=8^Hx-Female Genit Malg Nec
 ;;^UTILITY(U,$J,358.3,24200,2)
 ;;=^295222
 ;;^UTILITY(U,$J,358.3,24201,0)
 ;;=V10.81^^193^1651^2
 ;;^UTILITY(U,$J,358.3,24201,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,24201,1,1,0)
 ;;=1^V10.81
 ;;^UTILITY(U,$J,358.3,24201,1,8,0)
 ;;=8^Hx Of Bone Malignancy
 ;;^UTILITY(U,$J,358.3,24201,2)
 ;;=^295239
 ;;^UTILITY(U,$J,358.3,24202,0)
 ;;=V10.82^^193^1651^25
 ;;^UTILITY(U,$J,358.3,24202,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,24202,1,1,0)
 ;;=1^V10.82
 ;;^UTILITY(U,$J,358.3,24202,1,8,0)
 ;;=8^Hx-Malig Skin Melanoma
 ;;^UTILITY(U,$J,358.3,24202,2)
 ;;=^295240
 ;;^UTILITY(U,$J,358.3,24203,0)
 ;;=V10.83^^193^1651^31
 ;;^UTILITY(U,$J,358.3,24203,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,24203,1,1,0)
 ;;=1^V10.83
 ;;^UTILITY(U,$J,358.3,24203,1,8,0)
 ;;=8^Hx-Skin Malignancy Nec
 ;;^UTILITY(U,$J,358.3,24203,2)
 ;;=^295241
 ;;^UTILITY(U,$J,358.3,24204,0)
 ;;=V10.84^^193^1651^6
 ;;^UTILITY(U,$J,358.3,24204,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,24204,1,1,0)
 ;;=1^V10.84
 ;;^UTILITY(U,$J,358.3,24204,1,8,0)
 ;;=8^Hx Of Eye Malignancy
 ;;^UTILITY(U,$J,358.3,24204,2)
 ;;=^295242
 ;;^UTILITY(U,$J,358.3,24205,0)
 ;;=V10.85^^193^1651^3
 ;;^UTILITY(U,$J,358.3,24205,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,24205,1,1,0)
 ;;=1^V10.85
 ;;^UTILITY(U,$J,358.3,24205,1,8,0)
 ;;=8^Hx Of Brain Malignancy
 ;;^UTILITY(U,$J,358.3,24205,2)
 ;;=^295243
 ;;^UTILITY(U,$J,358.3,24206,0)
 ;;=V10.86^^193^1651^26
 ;;^UTILITY(U,$J,358.3,24206,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,24206,1,1,0)
 ;;=1^V10.86
 ;;^UTILITY(U,$J,358.3,24206,1,8,0)
 ;;=8^Hx-Malign Nerve Syst Nec
 ;;^UTILITY(U,$J,358.3,24206,2)
 ;;=^295244
 ;;^UTILITY(U,$J,358.3,24207,0)
 ;;=V10.88^^193^1651^16
 ;;^UTILITY(U,$J,358.3,24207,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,24207,1,1,0)
 ;;=1^V10.88
 ;;^UTILITY(U,$J,358.3,24207,1,8,0)
 ;;=8^Hx-Endocrine Malign Nec
 ;;^UTILITY(U,$J,358.3,24207,2)
 ;;=^295246
 ;;^UTILITY(U,$J,358.3,24208,0)
 ;;=238.0^^193^1652^1
 ;;^UTILITY(U,$J,358.3,24208,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,24208,1,1,0)
 ;;=1^238.0
 ;;^UTILITY(U,$J,358.3,24208,1,8,0)
 ;;=8^Bone and Articular Cartilage
 ;;^UTILITY(U,$J,358.3,24208,2)
 ;;=^81953
 ;;^UTILITY(U,$J,358.3,24209,0)
 ;;=238.1^^193^1652^3
 ;;^UTILITY(U,$J,358.3,24209,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,24209,1,1,0)
 ;;=1^238.1
 ;;^UTILITY(U,$J,358.3,24209,1,8,0)
 ;;=8^Connective and Oth Soft Tissue
 ;;^UTILITY(U,$J,358.3,24209,2)
 ;;=^267776
 ;;^UTILITY(U,$J,358.3,24210,0)
 ;;=238.2^^193^1652^17
 ;;^UTILITY(U,$J,358.3,24210,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,24210,1,1,0)
 ;;=1^238.2
 ;;^UTILITY(U,$J,358.3,24210,1,8,0)
 ;;=8^Skin
 ;;^UTILITY(U,$J,358.3,24210,2)
 ;;=^267777
 ;;^UTILITY(U,$J,358.3,24211,0)
 ;;=238.3^^193^1652^2
 ;;^UTILITY(U,$J,358.3,24211,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,24211,1,1,0)
 ;;=1^238.3
 ;;^UTILITY(U,$J,358.3,24211,1,8,0)
 ;;=8^Breast
 ;;^UTILITY(U,$J,358.3,24211,2)
 ;;=^81956
 ;;^UTILITY(U,$J,358.3,24212,0)
 ;;=238.4^^193^1652^15
 ;;^UTILITY(U,$J,358.3,24212,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,24212,1,1,0)
 ;;=1^238.4
 ;;^UTILITY(U,$J,358.3,24212,1,8,0)
 ;;=8^Polycythemia Vera
 ;;^UTILITY(U,$J,358.3,24212,2)
 ;;=^304816
 ;;^UTILITY(U,$J,358.3,24213,0)
 ;;=238.5^^193^1652^6
 ;;^UTILITY(U,$J,358.3,24213,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,24213,1,1,0)
 ;;=1^238.5
 ;;^UTILITY(U,$J,358.3,24213,1,8,0)
 ;;=8^Histiocytic and Mast Cells
 ;;^UTILITY(U,$J,358.3,24213,2)
 ;;=^267778
 ;;^UTILITY(U,$J,358.3,24214,0)
 ;;=238.6^^193^1652^14
 ;;^UTILITY(U,$J,358.3,24214,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,24214,1,1,0)
 ;;=1^238.6
 ;;^UTILITY(U,$J,358.3,24214,1,8,0)
 ;;=8^Plasma Cells
 ;;^UTILITY(U,$J,358.3,24214,2)
 ;;=^81973
 ;;^UTILITY(U,$J,358.3,24215,0)
 ;;=238.71^^193^1652^4
 ;;^UTILITY(U,$J,358.3,24215,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,24215,1,1,0)
 ;;=1^238.71
 ;;^UTILITY(U,$J,358.3,24215,1,8,0)
 ;;=8^Essential Thrombocythemia
 ;;^UTILITY(U,$J,358.3,24215,2)
 ;;=^334027
 ;;^UTILITY(U,$J,358.3,24216,0)
 ;;=238.72^^193^1652^7
 ;;^UTILITY(U,$J,358.3,24216,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,24216,1,1,0)
 ;;=1^238.72
 ;;^UTILITY(U,$J,358.3,24216,1,8,0)
 ;;=8^Low Grade Myelody Synd Lesion
 ;;^UTILITY(U,$J,358.3,24216,2)
 ;;=^334028
 ;;^UTILITY(U,$J,358.3,24217,0)
 ;;=238.73^^193^1652^5
 ;;^UTILITY(U,$J,358.3,24217,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,24217,1,1,0)
 ;;=1^238.73
 ;;^UTILITY(U,$J,358.3,24217,1,8,0)
 ;;=8^High Grade Myelody Synd Lesion
 ;;^UTILITY(U,$J,358.3,24217,2)
 ;;=^334029
 ;;^UTILITY(U,$J,358.3,24218,0)
 ;;=238.74^^193^1652^9
 ;;^UTILITY(U,$J,358.3,24218,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,24218,1,1,0)
 ;;=1^238.74
 ;;^UTILITY(U,$J,358.3,24218,1,8,0)
 ;;=8^Myelody Synd w/ 5q Deletion
 ;;^UTILITY(U,$J,358.3,24218,2)
 ;;=^334030
 ;;^UTILITY(U,$J,358.3,24219,0)
 ;;=238.75^^193^1652^10
 ;;^UTILITY(U,$J,358.3,24219,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,24219,1,1,0)
 ;;=1^238.75
 ;;^UTILITY(U,$J,358.3,24219,1,8,0)
 ;;=8^Myelodysplastic Syndrome
 ;;^UTILITY(U,$J,358.3,24219,2)
 ;;=^334031
 ;;^UTILITY(U,$J,358.3,24220,0)
 ;;=238.76^^193^1652^11
 ;;^UTILITY(U,$J,358.3,24220,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,24220,1,1,0)
 ;;=1^238.76
 ;;^UTILITY(U,$J,358.3,24220,1,8,0)
 ;;=8^Myelofibrosis w/Myeloid Metaplasia
 ;;^UTILITY(U,$J,358.3,24220,2)
 ;;=^334032
 ;;^UTILITY(U,$J,358.3,24221,0)
 ;;=238.77^^193^1652^16
 ;;^UTILITY(U,$J,358.3,24221,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,24221,1,1,0)
 ;;=1^238.77
 ;;^UTILITY(U,$J,358.3,24221,1,8,0)
 ;;=8^Post Transp Lymphoprolif d/o PTLD
 ;;^UTILITY(U,$J,358.3,24221,2)
 ;;=^336526
 ;;^UTILITY(U,$J,358.3,24222,0)
 ;;=238.79^^193^1652^12
 ;;^UTILITY(U,$J,358.3,24222,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,24222,1,1,0)
 ;;=1^238.79
 ;;^UTILITY(U,$J,358.3,24222,1,8,0)
 ;;=8^Oth Lymph/Hematopoietic Tissue
 ;;^UTILITY(U,$J,358.3,24222,2)
 ;;=^334033
 ;;^UTILITY(U,$J,358.3,24223,0)
 ;;=238.8^^193^1652^13
 ;;^UTILITY(U,$J,358.3,24223,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,24223,1,1,0)
 ;;=1^238.8
 ;;^UTILITY(U,$J,358.3,24223,1,8,0)
 ;;=8^Oth Lymph/Hematopoietic Tissue NEC
 ;;^UTILITY(U,$J,358.3,24223,2)
 ;;=^267779
 ;;^UTILITY(U,$J,358.3,24224,0)
 ;;=238.9^^193^1652^8
 ;;^UTILITY(U,$J,358.3,24224,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,24224,1,1,0)
 ;;=1^238.9
 ;;^UTILITY(U,$J,358.3,24224,1,8,0)
 ;;=8^Lymph/Hematopoietic Tissue NOS
 ;;^UTILITY(U,$J,358.3,24224,2)
 ;;=^267780
 ;;^UTILITY(U,$J,358.3,24225,0)
 ;;=239.0^^193^1653^5
 ;;^UTILITY(U,$J,358.3,24225,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,24225,1,1,0)
 ;;=1^239.0
 ;;^UTILITY(U,$J,358.3,24225,1,8,0)
 ;;=8^Digestive Neoplasm NOS
